Disparities in Cancer Prevention in the COVID-19 Era
John M. Carethers1, Rajarshi Sengupta2, Rea Blakey3, Antoni Ribas4, and Gypsyamber D’Souza5

ABSTRACT

Screening for cancer is a proven and recommended approach to prevent deaths from cancer; screening can locate precursor lesions and/or cancer at early stages when it is potentially curable. Racial and ethnic minorities and other medically underserved populations exhibit lower uptake of cancer screening than nonminorities in the United States. The COVID-19 pandemic, which disproportionately affected minority communities, has curtailed preventive services including cancer screening to preserve personal protective equipment and prevent spread of infection. While there is evidence for a rebound from the pandemic-driven reduction in cancer screening nationally, the return may not be even across all populations, with minority population screening that was already behind becoming further behind as a result of the community ravages from COVID-19. Fear of contracting COVID-19, limited access to safety-net clinics, and personal factors like, financial, employment, and transportation issues are concerns that are intensified in medically underserved communities. Prolonged delays in cancer screening will increase cancer in the overall population from pre-COVID-19 trajectories, and elevate the cancer disparity in minority populations. Knowing the overall benefit of cancer screening versus the risk of acquiring COVID-19, utilizing at-home screening tests and keeping the COVID-19-induced delay in screening to a minimum might slow the growth of disparity.

The benefit of cancer screening and identifying cancers early has been rigorously demonstrated to reduce cancer-related deaths, and is endorsed by multiple medical societies and insurers. Several randomized control trials regarding screening for specific cancers have demonstrated enormous benefits in reducing patient mortality from cancer when screened (1–3); earlier cancer detection by screening drives substantial improvements in 5-year survival rates among those diagnosed with localized instead of metastatic disease (90% vs. 14% survival for colon and 99% vs. 28% survival for breast cancer; ref. 4; https://seer.cancer.gov/csr/1975_2017/). These screening benefits are clear, but screening does have harms as well, including false positives or overdiagnosis as some advanced sensitive screening methods detect not-as-specific biomarkers and/or smaller lesions without a reduction in incidence of invasive cancers, and can lead to additional unnecessary follow-up testing (5–7).

Many professional societies have evidence-based recommendations for the use of the screening tests for breast, cervical, and colorectal cancer among average-risk individuals. Even though the benefits of cancer screening outweigh the potential risks, a substantial percentage of individuals who are eligible are not up to date with their screening regimen. For example, in 2018, 31% of adults ages 50–75 years were not up to date with colorectal cancer screening (8). Notably, individuals who are not up to date with cancer screening recommendations are disproportionately found in medically underserved segments of the U.S. population, including racial and ethnic minorities. For example, 69% of Whites ages 50–75 years are up to date on colorectal cancer screening compared with 66% of African Americans, 59% of Hispanics, and only 56% of American Indian/Alaska Natives (9). In addition, according to recent estimates, women in the lowest income bracket are significantly less likely to be up to date with breast cancer screening than...
women in the highest income bracket; the same income differential is observed for colorectal cancer screening, with those in the lowest income bracket significantly less likely to be up to date with colorectal cancer screening than adults who are in higher income brackets (Fig. 1; ref. 10).

The COVID-19 pandemic that commenced in March 2020 in the United States caused a stark shut down of preventive clinical services including cancer screening to prevent spread of infection and preserve personal protective equipment. Compared with 2019, screening tests for breast and colorectal cancer were decreased by 89.2% and 84.5%, respectively, by April 2020 (11). The level and vigor of rebound from the COVID-19–induced delay for cancer screening (Fig. 2) will determine the degree and extent of missed preventive tests for all cancers, and will drive the long-term consequence of projected increased cancer-related deaths (12). For medically underserved populations, such as African Americans, who have the highest rates of colorectal cancer incidence and mortality, screening through the use of systemized patient navigation has been shown to reduce and eliminate colorectal cancer disparities (13); the actual attainment of elimination of disparities in clinical practice has not yet been achieved. In the face of the COVID-19, the potential reduction or elimination of colorectal cancer disparities is further threatened, and could reverse the years of steady progress toward equity in screening (14).

Medically underserved populations have long demonstrated structural socioeconomic disadvantages along with numerous barriers to attaining medical access and use. Disadvantages such as low income, living in neighborhoods with food deserts, and possessing little or no insurance all hinder use of preventive services such as cancer screening. In addition, there is often higher prevalence of cancer risk factors such as tobacco and alcohol use and ingestion of high-fat, high-caloric diets that predispose these populations to a higher risk of cancer formation (15). In addition, certain medically underserved populations have long-standing fear of “going to the doctor” for cultural and/or historical exploitation reasons (16).

COVID-19’s arrival into the human population has disproportionately affected vulnerable and medically underserved populations (17), exacerbating preexisting fears and creating new ones in these populations that may extend beyond the length of the pandemic to have disproportional consequences for preventive care. Fear of COVID-19 exposure at a medical site (even when clinical precautions may have made risk lower than community exposure) postpones preventive care. For others without fear of coming to clinic, access may be limited by other COVID-19–related changes such as changes in local transportation, work schedule issues, and lack of childcare, which may disproportionately impact communities which are already medically underserved. Effects of stay-at-home policies and travel restrictions, loss of or lack of financial savings, and loss of any employment (due to loss of job or getting sick on the job as an essential employee in a high COVID-19 risk situation) all undoubtedly worsen the ability to obtain preventive care.

Early during the pandemic, academic and community practices ceased cancer screenings and other elective procedures at the bequest of the U.S. Surgeon General (18); for example, it is estimated that between March and May 2020 there were 95,000 missed screens for colorectal cancer in the United States (https://ehrn.org/delayed-cancer-screenings-a-second-look/) among the estimated 67% of eligible Americans utilizing colorectal cancer screening. With reestablishment of colonoscopic screening, the backlog will take time to be reduced, depending on practice pace, physician availability, and patient utilization (Fig. 2). The other 33% of eligible Americans who have never utilized colorectal cancer screening for a variety of reasons are disproportionately from medically underserved populations (19). COVID-19 has the potential to shrink the number of medically underserved that were already in the screening utilization group, and expand the nonutilization group. Professional gastroenterology organizations have called for increase in use of noninvasive stool screening tests that are inexpensive and sensitive that can ensure appropriate and broad screening uptake throughout medically underserved populations (https://www.medscape.com/viewarticle/935288). Noninvasive testing that is positive needs to be followed by a diagnostic colonoscopy which can create a financial challenge if the colonoscopy is not covered by insurance or unavailable in the area.
The immediate risk of acquiring COVID-19 may seem much more pressing than the potential benefit of cancer screening. Weighing the risks and benefits of elective procedures like cancer screening during the COVID-19 pandemic can be unclear (Fig. 3). Short-term delays in screening (e.g., 6–12 months) among asymptomatic individuals might be reasonable and were universally recommended and enacted because of the immediate risks associated with the COVID-19 surge. However, as the pandemic timeline extends, and the delay in screening lengthens, so does the cancer risk. Modeling studies of the impact of a 12-month delay in cancer diagnosis increase deaths rates (5 years after diagnosis) by approximately 8% for breast cancer and approximately 16% for colorectal cancer (20). Thus, while short-term interruptions in screening may be low risk, longer intervals extend the risk of delayed detection of cancers.

Figure 2.
Scenarios for cancer prevention after COVID-19 surges. Scenario A indicates a rapid recovery under 1 year with fairly rapid clearance of the backlog. Scenario B depicts a delayed return to historical screening trends over 1–3 years, with a much longer clearance of backlog over several years. Scenario C depicts a situation in which we never get back to historical trends, creating a public health crisis. Delays in returning to baseline or higher levels of screening with reverse gains, causing additional preventable deaths from cancer. Estimates for excess deaths are from a baseline of delay of 6-months for breast and colorectal cancers as modeled in Sharpless (12).

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Factors affecting scenario</th>
<th>Relative # cancer deaths from baseline trajectory</th>
</tr>
</thead>
</table>
| A        | Rapid return to screening trajectory within 6–12 months | • No further COVID-19 shutdowns of clinical capacity  
• Unrestricted screening capacity | ~1,000 annually |
| B        | Delayed return to trajectory over 1–3 years | • Restricted/delayed screening capacity due to COVID-19 testing (preventing some screening services) and social distancing | 1,000–5,000 annually |
| C        | Prolonged return to trajectory over several years | • Prolonged screening capacity restraints due to large backlogs of delayed screening  
• Potential public and individual awareness for screening wanes  
• Exacerbation of fears for clinic settings due to ongoing pandemic | ≥5,000–10,000 annually |

Figure 3.
Benefits versus risks of cancer screening during the COVID-19 pandemic.

Screening benefits
- Early disease detected → large benefit
- Screen negatives, healthy → low benefit
- Higher benefit among those at higher risk:
  - older
  - family or personal history
  - under-screened

Earlier detection and reduced cancer mortality when screened

Risk of getting SARS-CoV-2 when screened
- Unknown but low with proper PPE
- Higher when SARS-CoV-2 surging locally, taking public transportation, and not wearing proper PPE

Screening risks
- Overdiagnosis
- Unnecessary follow-up
- False positives and negatives
Cancer prevention by screening is a proven approach to reduce risk from dying from cancer; if utilized universally to the identical extent in all racial and ethnic populations, screening can greatly reduce disparities. COVID-19 has caused delay of population screening, and we fear it will exacerbate currently observed disparities in screening. Some professional societies aptly recommend noninvasive approaches to screening, several of which may be originated in the home setting. For example, self-sampling has been proven to be highly effective both for cervical cancer screening, using human papillomavirus DNA sampling (21), and for colorectal cancer screening, using fecal immunochemical testing or fecal DNA sampling (1, 22). Some at-home tests, such as fecal DNA sampling for colorectal cancer, may be as sensitive as other tests administered in the clinical setting (22). At-home testing may improve uptake of screening for medically underserved patients in conjunction with patient education and availability of the test to the patient in the home; however, screening tests administered in the home setting, if found positive, often require a follow-up test in the clinical setting that may be difficult to execute in this population. We must be vigilant to: (i) keep the COVID-19–induced delay in cancer screening to a minimum time, (ii) utilize services such as navigation to continue inroads into reducing disparities in screening rates between populations, (iii) increase population screening rates nationally even in the face of a pandemic for the long-term health of our nation, and (iv) continue to improve upon methods used to detect clinically impactful precursors and presence of cancers at its earliest stage for cancer prevention and patient cure.

Disclosure of Potential Conflicts of Interest

A. Ribas reports grants from Agilent and Bristol-Myers Squibb (research funding), personal fees from Amgen, AstraZeneca, Checkmate, Merck, Novartis, Sanofi, and Vedanta (honorary from consulting) and 4C Biomed, Apricity, Arcus, Highlight, Compugen, ImaginAb, MapKure, Merus, Rgenix, Lutris, PACT Pharma, and Tango (SAB member and stock holder) outside the submitted work. G. D’Souza reports grants from NIH during the conduct of the study. No potential conflicts of interest were disclosed by the other authors.

Acknowledgments

The following authors were supported by the United States Public Health Service: R35DE026631 (to G. D’Souza), R01CA206010 (to J.M. Carethers), and R35 CA197633 (to A. Ribas). J.M. Carethers also received support from the A. Alfred Taubman Medical Research Institute of the University of Michigan.

Received August 27, 2020; revised September 1, 2020; published first September 16, 2020.

References

Disparities in Cancer Prevention in the COVID-19 Era

John M. Carethers, Rajarshi Sengupta, Rea Blakey, et al.

Cancer Prev Res  Published OnlineFirst September 17, 2020.

Updated version  Access the most recent version of this article at:
doi:10.1158/1940-6207.CAPR-20-0447

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://cancerpreventionresearch.aacrjournals.org/content/early/2020/10/13/1940-6207.CAPR-20-0447. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.